TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11260171

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg of zinc sulphate orally
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of zinc sulphate orally
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of zinc sulphate orally
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 104
Study: 9499663

Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis in a centralized laboratory
Number of subjects: 1115
Study: 8427168

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg 3 times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3687152

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (single-frequency pure tone 2 kHz, 120 dB, 5 sec)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (sawtooth-modulated pure tone 0.5-2.0 kHz, modulation frequency 10 Hz, 120 dB, 5 sec)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (low-frequency sawtooth-modulated pure tone 0.1-0.3 kHz, modulation frequency 10 Hz, 120 dB, 5 sec)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Light stimulation (electronic photographic flash, luminous intensity 25 x 106 Lux/10-3 sec, 8 flash sequences in 10 sec)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sham stimulation (no acoustic or light-optic signals)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Genuine light stimulation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sham light stimulation
Number of subjects: 85
Study: 29921575

Group type: EXPERIMENTAL
Intervention: Shen-Shuai-Ning (SSN) granule, 5 g three times daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (baseline medications and dialysis prescriptions)
Number of subjects: 60
Study: 26162647

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24613110

Group type: EXPERIMENTAL
Intervention: recombinant human interleukin 11, 1.5 mg subcutaneously
Number of subjects: 40

Group type: COMPARATOR
Intervention: distilled water (placebo)
Number of subjects: 40
Study: 23241457

Group type: EXPERIMENTAL
Intervention: Hybrid sirolimus-eluting stents with bioresorbable polymers (Orsiro)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Everolimus-eluting stents with durable polymers (Xience Prime/Xpedition)
Number of subjects: 330
Study: 20378829

Group type: EXPERIMENTAL
Intervention: TU-100 2.5 g tid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TU-100 5 g tid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TU-100 7.5 g/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18369202

Group type: EXPERIMENTAL
Intervention: Staging system based on HRCT and PFTs
Number of subjects: 215

Group type: COMPARATOR
Intervention: HRCT threshold of 20%
Number of subjects: 215

Group type: COMPARATOR
Intervention: FVC threshold of 70%
Number of subjects: 215
Study: 16516788

Group type: EXPERIMENTAL
Intervention: Aspheric profile PRK
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 74
Study: 12625641

Group type: EXPERIMENTAL
Intervention: Treadmill therapy with partial body weight support (BWS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Locomotor training
Number of subjects: 0
Study: 11012471

Group type: EXPERIMENTAL
Intervention: Polyurethane PEG catheter
Number of subjects: 106

Group type: COMPARATOR
Intervention: Silicone PEG catheter
Number of subjects: 106
Study: 8815970

Group type: EXPERIMENTAL
Intervention: Oxymizer device
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transtracheal catheter
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 14
Study: 1364955

Group type: EXPERIMENTAL
Intervention: Cyclo-cryocoagulation as a single method applied to 12 eyes
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined cryosurgical method (trans-scleral panretinal cryocoagulation + cyclo-cryocoagulation) applied to 26 eyes
Number of subjects: 38
Study: 6697075

Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: indomethacin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: tolfenamic acid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: azapropazone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: carprofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 90

Group type: COMPARATOR
Intervention: ketoprofen
Number of subjects: 90

Group type: COMPARATOR
Intervention: proquazone
Number of subjects: 90
Study: 30607578

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT) with negative minimal residual disease after 2 cycles of consolidation
Number of subjects: 223
Study: 30258440

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27130049

Group type: EXPERIMENTAL
Intervention: 0.5gI/kg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.4gI/kg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.3gI/kg
Number of subjects: 57
Study: 24708604

Group type: EXPERIMENTAL
Intervention: Fundamental movement skill competency (locomotor skills)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Fundamental movement skill competency (object-control skills)
Number of subjects: 460
Study: 22394493

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Group Therapy (CBGT); 12-session protocol
Number of subjects: 165
Study: 19636577

Group type: EXPERIMENTAL
Intervention: FDG-PET-CT
Number of subjects: 80

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: PET
Number of subjects: 80

Group type: COMPARATOR
Intervention: CT
Number of subjects: 80

Group type: COMPARATOR
Intervention: PET-CT
Number of subjects: 80
Study: 18853113

Group type: EXPERIMENTAL
Intervention: Shugan Jianpi Granule (SJG) 24 g three times a day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shugan Jianpi Granule (SJG) 24 g three times a day + Smecta 15 g three times a day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 24
Study: 16447880

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng injection (SFI) 100 ml, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerine injection 10 mg, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Number of subjects: 60
Study: 12451368

Group type: EXPERIMENTAL
Intervention: 5% tea tree oil shampoo
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 10360922

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (10 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7857113

Group type: EXPERIMENTAL
Intervention: Daily application of strong sunscreen
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 1928879

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Isoetharine
Number of subjects: 103
Study: 7049029

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride, 500 mg orally four times daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rosaramicin, 250 mg orally four times daily for 7 days
Number of subjects: 100
Study: 31257264

Group type: EXPERIMENTAL
Intervention: MFGM 1.0 g + glucosamine 1.5 g
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29466164

Group type: EXPERIMENTAL
Intervention: RV3-BB (neonatal schedule)
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: RV3-BB (infant schedule)
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Combined RV3-BB (neonatal and infant schedule)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study: 26262771

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eplerenone (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eplerenone (multiple doses)
Number of subjects: 12
Study: 25249056

Group type: EXPERIMENTAL
Intervention: Small Group (SG) treatment (12 members/group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Large Group (LG) treatment (30 members/group)
Number of subjects: 66
Study: 22499292

Group type: EXPERIMENTAL
Intervention: SBP target <130 mmHg
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: SBP target 130-149 mmHg
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Treated hypertension at baseline
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Management at a larger site
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: SBP in target at 6 months
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Missed appointments
Number of subjects: 1041
Study: 20308641

Group type: EXPERIMENTAL
Intervention: CONCERNS + B (bupropion hydrochloride sustained release)
Number of subjects: 349

Group type: COMPARATOR
Intervention: STANDARD + B (bupropion hydrochloride sustained release)
Number of subjects: 349

Group type: COMPARATOR
Intervention: STANDARD + P (placebo)
Number of subjects: 349

Group type: COMPARATOR
Intervention: CONCERNS + P (placebo)
Number of subjects: 349
Study: 17579339

Group type: EXPERIMENTAL
Intervention: Consistent condom use (100% of acts) for the past 7 days
Number of subjects: 414

Group type: COMPARATOR
Intervention: No condom use reported
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Number of unprotected acts
Number of subjects: 414
Study: 15083634

Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure lowering regimen
Number of subjects: 6105
Study: 11457749

Group type: EXPERIMENTAL
Intervention: MMP-2 levels in tissue homogenates and isolated inferior mesenteric SMCs from patients with AAAs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Histological examination of venous tissue from patients with AAAs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: In situ zymography
Number of subjects: 34
Study: 9870006

Group type: EXPERIMENTAL
Intervention: Dual site atrial pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single site atrial pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support pacing control (DDI at 50 ppm or VDI)
Number of subjects: 0
Study: 8058230

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 100
Study: 3291371

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adriamycin plus cyclophosphamide
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cis-platinum plus 5-fluorouracil plus cyclophosphamide
Number of subjects: 180
Study: 31126270

Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride toothpaste and usual care
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1200
Study: 28569390

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47
Study: 26493429

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow ups (Tele-Nursing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 60
Study: 23454666

Group type: EXPERIMENTAL
Intervention: computer-based MetS Program (CBMP)
Number of subjects: 750

Group type: COMPARATOR
Intervention: printed educational material (PEM)
Number of subjects: 750
Study: 22051486

Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 60
Study: 19691545

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive‐behavior therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed treatment group (waitlist control)
Number of subjects: 24
Study: 15190831

Group type: EXPERIMENTAL
Intervention: Viagra combined with behavior therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavior therapy alone (control group)
Number of subjects: 60
Study: 10365361

Group type: EXPERIMENTAL
Intervention: Mania-ADHD
Number of subjects: 151

Group type: COMPARATOR
Intervention: ADHD only
Number of subjects: 151
Study: 7741071

Group type: EXPERIMENTAL
Intervention: DES (500 mg daily injection) for 7 days before LH-RH analogue (3.6 mg of Zoladex depot)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 7 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DES (500 mg injection) for 7 days simultaneously with LH-RH analogue
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 3 days
Number of subjects: 16
Study: 1970298

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg daily (increased to 20 mg if necessary)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol 50 mg daily (increased to 100 mg if necessary)
Number of subjects: 12
Study: 7027819

Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchospasmin)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Terbutalin (Bricanyl)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec)
Number of subjects: 90
Study: 31775686

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine (IPTp-SP) administered during pregnancy
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Having secondary or higher education
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Attending ≥4 ANC visits
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Having first antenatal booking at < 17 weeks
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Adequate knowledge on IPTp-SP
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Health care workers' knowledge about IPTp-SP
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Availability of SP in health facilities
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Direct Observed Therapy (DOT) for SP administration
Number of subjects: 556
Study: 28267474

Group type: EXPERIMENTAL
Intervention: Azimilide 75 mg daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 27852711

Group type: EXPERIMENTAL
Intervention: Medication treatment (MT) plus percutaneous transluminal angioplasty and stenting (PTAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication treatment (MT) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication treatment (MT) plus PTAS
Number of subjects: 0
Study: 25118680

Group type: EXPERIMENTAL
Intervention: Cement-free prostheses
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cemented shaft implants
Number of subjects: 105
Study: 21726302

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 801
Study: 18570696

Group type: EXPERIMENTAL
Intervention: Sourdough bread
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole wheat breads
Number of subjects: 10
Study: 17445639

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day plus Tolterodine 2 mg (twice a day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg (twice a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No medical treatment (control group)
Number of subjects: 120
Study: 15649317

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1996
Study: 12202454

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study: 9825504

Group type: EXPERIMENTAL
Intervention: Acute viral hepatitis B patients with severe form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute viral hepatitis B patients with moderate form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute viral hepatitis B patients (general)
Number of subjects: 0
Study: 8085623

Group type: EXPERIMENTAL
Intervention: Indomethacin 2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2782514

Group type: EXPERIMENTAL
Intervention: 5th grade reading level booklet
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 10th grade reading level booklet
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no smoking booklet)
Number of subjects: 129
Study: 31303116

Group type: EXPERIMENTAL
Intervention: High adherers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low adherers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reminder interventions
Number of subjects: 18
Study: 28640984

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for colorectal cancer
Number of subjects: 5680

Group type: COMPARATOR
Intervention: Traditional open surgery for colorectal cancer
Number of subjects: 5680
Study: 26475583

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 32
Study: 23356392

Group type: EXPERIMENTAL
Intervention: 125 µg fluticasone dipropionate and 25 µg salmeterol, two actuations twice daily, by either separate or combination ICS/LABA inhalers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Underuse of inhalers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Overuse of inhalers
Number of subjects: 111
Study: 21329753

Group type: EXPERIMENTAL
Intervention: Major depressive disorder
Number of subjects: 104

Group type: COMPARATOR
Intervention: Antidepressant medications
Number of subjects: 104
Study: 22009824

Group type: EXPERIMENTAL
Intervention: Titanium-coated lumbar interbody fusion system
Number of subjects: 94
Study: 17923575

Group type: EXPERIMENTAL
Intervention: Cell saver
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control
Number of subjects: 226
Study: 14683739

Group type: EXPERIMENTAL
Intervention: Flu vaccination
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 296
Study: 12421196

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Laudanosine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 25
Study: 9803088

Group type: EXPERIMENTAL
Intervention: AIDS education intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videos and informational cartoons as media for intervention
Number of subjects: 0
Study: 8128175

Group type: EXPERIMENTAL
Intervention: Cisapride (5 mg three times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg three times daily)
Number of subjects: 60
Study: 2491470

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 163937

Group type: EXPERIMENTAL
Intervention: Combined treatment with 0.3 percent 'Neutralrot' eye drops and radiation with daylight lamp HPR 125 W.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye drops of corticosteroid content.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular inoculation with Interferonogen.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 'Okuzell-Coldan' eye drops as placebo.
Number of subjects: 0
Study: 31120504

Group type: EXPERIMENTAL
Intervention: Text messaging intervention supported by a smartphone application
Number of subjects: 112
Study: 31565969

Group type: EXPERIMENTAL
Intervention: NCAA Fact Sheet for Coaches (intervention condition)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 779
Study: 28526538

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (3.6 mg/kg intravenously every 21 days)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 602
Study: 26087637

Group type: COMPARATOR
Intervention: diclofenac sodium 100 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Alflutop injection 1 ml per day for 20 days, then 2 ml intraarticular twice weekly in the following month
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: diacerein (diaflex, 'Rompharm Company') 50 mg twice daily for 3 months
Number of subjects: 86
Study: 23921483

Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (100 μg daily for 2 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (200 μg daily for 6 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (100 μg and 200 μg daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast (after 8 weeks washout)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chromium-enriched yeast
Number of subjects: 11
Study: 21519733

Group type: EXPERIMENTAL
Intervention: Glutamine group (50 g L-glutamine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Carbohydrate group (12.5% maltodextrine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo group (water, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fasted group (conventional preoperative fasting of 8 hours)
Number of subjects: 56